about
Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatmentsRadiotherapy and "new" drugs-new side effects?Creating a data exchange strategy for radiotherapy research: towards federated databases and anonymised public datasetsGlioblastoma multiforme: emerging treatments and stratification markers beyond new drugsExploring the role of cancer stem cells in radioresistanceβ₁Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapyExperimental evaluation of functional imaging for radiotherapy.Epidermal growth factor receptor inhibitors for radiotherapy: biological rationale and preclinical results.An optimized small animal tumour model for experimentation with low energy protons.Late onset Li-Fraumeni Syndrome with bilateral breast cancer and other malignancies: case report and review of the literature.Effect of combined irradiation and EGFR/Erb-B inhibition with BIBW 2992 on proliferation and tumour cure in cell lines and xenografts.EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation.Establishment of a small animal tumour model for in vivo studies with low energy laser accelerated particlesComparison study of in vivo dose response to laser-driven versus conventional electron beam.Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results.Molecular targeting in radiotherapy of lung cancer.Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme.DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity.Internal and external validation of an ESTRO delineation guideline - dependent automated segmentation tool for loco-regional radiation therapy of early breast cancer.Improving external beam radiotherapy by combination with internal irradiationRegional radiotherapy in high-risk breast cancer: is the issue solved?Increase in Tumor Control and Normal Tissue Complication Probabilities in Advanced Head-and-Neck Cancer for Dose-Escalated Intensity-Modulated Photon and Proton Therapy.TCP and NTCP in preclinical and clinical research in Europe.Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy.EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms.Clinical biomarkers of kinase activity: examples from EGFR inhibition trials.PRONTOX - proton therapy to reduce acute normal tissue toxicity in locally advanced non-small-cell lung carcinomas (NSCLC): study protocol for a randomised controlled trial.Cancer stem cells and radiotherapy.Concept for individualized patient allocation: ReCompare--remote comparison of particle and photon treatment plans.Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: differences between antibodies and TK inhibitors.Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and TherapyCancer stem cells at the crossroads of current cancer therapy failures--radiation oncology perspective.Individualization of cancer treatment from radiotherapy perspective.Pre-clinical research in small animals using radiotherapy technology--a bidirectional translational approach.Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure.Modeling in vivo relative biological effectiveness in particle therapy for clinically relevant endpoints.EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks.Proton radiography for inline treatment planning and positioning verification of small animals.The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).Modeling tumor control probability for spatially inhomogeneous risk of failure based on clinical outcome data.
P50
Q26766132-8EB4542E-9B62-40E1-B111-FD17D5CEB493Q26861498-0A69D5FF-D12E-4DCB-A45D-7D0F71648D72Q26864472-38A9752C-9C89-4288-BDE4-8AFAC7967F63Q28082603-EA081224-FE37-4707-8BBC-540F8809F3A7Q28282037-07ab842a-47f6-164f-dc51-1052966e5ae7Q30427521-E71AF4EC-9E2F-42C8-B17A-65A6EB792898Q33312903-12243D5A-663E-4DF4-AC33-20790ABB89B5Q33353609-80728E91-D69F-4CCC-9BD3-A3283AC46C37Q33703716-299C307D-517B-41FB-BC3F-EDD19E598877Q34294432-88BA564E-278A-425F-8DEF-EBD53C3D8FECQ34740289-6D82B2BD-7475-477D-AFBE-8183BB518BCDQ34782417-47B97226-2B11-44C0-8C17-C7945E214941Q35095806-4957B82C-5EE5-4C95-9964-1CDB495F010DQ35544761-6B7A5469-994F-4C62-A72F-61F094AFB5A6Q35902858-046B0514-D258-4FA3-9D66-CCCF93D71CC5Q35955505-B44E9B74-39F7-4E63-AED8-D736F42EC7B6Q36010006-0FE9D112-1146-4297-A7CC-F6D57F8D287DQ36073749-DDF161A9-893F-43A6-A322-BDCBDCCBA791Q36151932-2D970470-55BE-4324-AE34-649BF16E4EFCQ36235732-CECD08AE-2023-499F-8E8F-C8531A231426Q36235737-EF747326-42E0-48DD-AD44-B2DEACC8804FQ36300626-AF80420D-71E2-4303-8D09-A113F314473EQ36315760-2264AE36-6B28-4D42-88B7-1B8EC6A17C61Q36568890-40D14856-8DAA-4227-8314-4EB045A4EEDAQ36821522-B0298235-4451-483D-B0E8-55D02FBA4B27Q37144140-BBAD0118-6E26-40BA-ABF2-FF0820CFDE05Q37417131-8ECA67CE-456C-4781-AD02-85D00C2D1422Q37453248-44535E0E-16B3-400D-B156-3C199FB3A12DQ37600627-D172146A-EA6F-4726-B636-5962EB56D50FQ37628728-8EF9D2AA-DDCC-4EED-82AC-901D184EF052Q37689802-B72AE6B2-3161-40F3-BB58-1117DED95889Q37706840-d7d08eb3-443f-625d-b017-572d3a81c5aaQ37989616-02478DE3-9260-4AC7-899D-127CF8A11E4AQ38240079-FFF23AAF-1BA8-4429-B846-D2729A4F7CBCQ38412352-AD6BA002-0A8A-4F05-85F2-CE7AA84EA44DQ38604190-D7455937-F9EC-47FC-8272-F96F0A7A0D91Q38609721-BEDCFF9D-36B4-4D53-9F11-F09E3840848BQ38611399-FE71D2B3-0D4A-4FF4-A122-7F175087337AQ38686682-F2B57383-B636-4DA9-8162-130EFEF96821Q38694018-7A36FD6B-DA18-471D-9D5D-1B5DFEDA2F80
P50
description
German researcher
@en
wetenschapper
@nl
name
Mechthild Krause
@ast
Mechthild Krause
@en
Mechthild Krause
@es
Mechthild Krause
@nl
type
label
Mechthild Krause
@ast
Mechthild Krause
@en
Mechthild Krause
@es
Mechthild Krause
@nl
altLabel
M Krause
@en
M Krause
@nl
prefLabel
Mechthild Krause
@ast
Mechthild Krause
@en
Mechthild Krause
@es
Mechthild Krause
@nl
P108
P106
P1153
7202278334
P21
P214
2517148390869910830008
P31
P496
0000-0003-1776-9556
P734
P7859
lccn-n2016188872